TB Infection Control

Discussion Brief

In areas where drug sensitivity testing (DST) and capacity for treating drug resistant tuberculosis is limited, patients suspected of having MDR-TB may need to be transported from their community to a regional or national facility for diagnosis or treatment. Likewise, sputum samples requiring culture or DST may need to be taken to a distant lab. This discussion covers the precautions that should be taken to prevent TB infection of people involved in transporting patients, and to maintain the integrity of the sputum sample during transportation.
Sign in to read complete brief

• Principles of out-patients MDR-TB Treatment & Management
• Number of MDR/XDR TB Patients under Treatment: Implications for the Future
• Nurses as providers of emotional support to patients with MDR-TB
• What should FSU Countries do to reduce nosocomial TB transmission? –especially MDR-TB
• Acceptance of Anti-Retroviral Therapy among Patients with HIV and TB in Rural Malawi is Low and Associated with Cost of Transport

• Fwd: [tb-update] Week of July 11 to July 17, 2010
• RE: [MDR-TB Treatment & Prevention] [MDR-TB Treatment & Prevention] in Afghanistan
• Xpert MTB/Rif
• How long are MDR-TB patients infectious on EFFECTIVE therapy?
• CDC NPIN TB-update: Week of February 20 to February 26, 2011